Ratings by Leerink (David Risinger)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/1/2026 | Latigo Biotherapeutics | LTGO | New Coverage | Outperform (N/A) |
22.02 (21.69) |
-1.5% | Details | |
| 8/25/2026 | Scribe Therapeutics Inc | SCTX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/18/2026 | Scribe Therapeutics Inc | SCTX | New Coverage | Outperform (N/A) |
21.19 (29.85) |
40.87% | Details | |
| 8/14/2026 | Ligand Pharma | LGND | New Coverage | Outperform (N/A) |
288.82 (289.58) |
0.26% | Details | |
| 8/7/2026 | Halozyme Therapeutics | HALO | Upgrade | Outperform (Market Perform) |
85.76 (107.61) |
25.48% | Details | |
| 7/17/2026 | Johnson & Johnson | JNJ | Maintain | Outperform (N/A) |
|
Details | ||
| 5/26/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/21/2026 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 5/13/2026 | Johnson & Johnson | JNJ | Upgrade | Outperform (Market Perform) |
224.26 (269.36) |
20.11% | Details | |
| 4/27/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2026 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 4/24/2026 | First Tracks Biotherapeutics | TRAX | New Coverage | Outperform (N/A) |
19.00 (37.41) |
96.89% | Details | |
| 4/16/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/15/2026 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/7/2026 | Halozyme Therapeutics | HALO | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/1/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/1/2026 | Pfizer | PFE | Maintain | Market Perform (N/A) |
|
Details | ||
| 4/1/2026 | Centessa Pharmaceuticals | CNTA | Downgrade | Market Perform (Outperform) |
39.72 (40.50) |
1.96% | Details | |
| 3/26/2026 | Oruka Therapeutics | ORKA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2026 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2026 | Tenax Therapeutics | TENX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/5/2026 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/25/2026 | Vaxcyte | PCVX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/25/2026 | Tectonic Therapeutics Inc. | TECX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/13/2026 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/12/2026 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 1/6/2026 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 1/5/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/18/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/15/2025 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 12/2/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/24/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2025 | Vaxcyte | PCVX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2025 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2025 | Eli Lilly | LLY | Upgrade | Outperform (Market Perform) |
924.37 (1120.01) |
21.16% | Details | |
| 10/24/2025 | ImageneBio | IMA | New Coverage | Outperform (N/A) |
7.39 (5.01) |
-32.21% | Details | |
| 10/15/2025 | Johnson & Johnson | JNJ | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/14/2025 | Halozyme Therapeutics | HALO | Upgrade | Market Perform (Underperform) |
65.33 (85.76) |
31.27% | Details | |
| 10/2/2025 | Halozyme Therapeutics | HALO | Maintain | Underperform (N/A) |
|
Details | ||
| 9/30/2025 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 9/25/2025 | Vertex | VRTX | Upgrade | Outperform (Market Perform) |
376.62 (515.37) |
36.84% | Details | |
| 9/24/2025 | Metsera Inc | MTSR | Downgrade | Market Perform (Outperform) |
53.00 (70.50) |
33.02% | Details | |
| 9/17/2025 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 9/9/2025 | Metsera Inc | MTSR | New Coverage | Outperform (N/A) |
35.10 (53.00) |
51% | Details | |
| 9/4/2025 | Sanofi | SNY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/13/2025 | Theravance Biopharma | TBPH | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/12/2025 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 8/7/2025 | Eli Lilly | LLY | Downgrade | Market Perform (Outperform) |
746.37 (924.37) |
23.85% | Details | |
| 8/5/2025 | Vertex | VRTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/13/2025 | Johnson & Johnson | JNJ | Downgrade | Market Perform (Outperform) |
154.14 (224.26) |
45.49% | Details | |
| 5/13/2025 | Halozyme Therapeutics | HALO | Downgrade | Underperform (Market Perform) |
66.58 (107.61) |
61.63% | Details | |
| 5/6/2025 | Vertex | VRTX | Downgrade | Market Perform (Outperform) |
500.19 (376.62) |
-24.7% | Details | |
| 5/2/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2025 | Pfizer | PFE | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/10/2025 | Tenax Therapeutics | TENX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/3/2025 | Structure Therapeutics | GPCR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/7/2025 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2025 | Tectonic Therapeutics Inc. | TECX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/11/2024 | Pfizer | PFE | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/27/2024 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/20/2024 | Centessa Pharmaceuticals | CNTA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2024 | Theravance Biopharma | TBPH | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/12/2024 | Bristol-Myers Squibb Co. | BMY | Upgrade | Outperform (Market Perform) |
59.82 (63.76) |
6.59% | Details | |
| 11/6/2024 | Vaxcyte | PCVX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2024 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/4/2024 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/1/2024 | Halozyme Therapeutics | HALO | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/24/2024 | Tenax Therapeutics | TENX | New Coverage | Outperform (N/A) |
4.32 (1.96) |
-54.63% | Details | |
| 10/21/2024 | Roivant Sciences | ROIV | Maintain | Outperform (N/A) |
|
Details | ||
| 10/7/2024 | Pfizer | PFE | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/4/2024 | Halozyme Therapeutics | HALO | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/3/2024 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 9/17/2024 | Oruka Therapeutics | ORKA | New Coverage | Outperform (N/A) |
25.90 (92.09) |
255.56% | Details | |
| 8/6/2024 | Theravance Biopharma | TBPH | Downgrade | Market Perform (Outperform) |
9.59 (17.02) |
77.48% | Details | |
| 7/31/2024 | Pfizer | PFE | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/24/2024 | Tectonic Therapeutics Inc. | TECX | New Coverage | Outperform (N/A) |
16.44 (29.15) |
77.31% | Details | |
| 7/9/2024 | HilleVax, Inc. | HLVX | Downgrade | Market Perform (Outperform) |
1.64 (2.09) |
27.44% | Details | |
| 4/16/2024 | AnaptysBio | ANAB | New Coverage | Outperform (N/A) |
21.27 (55.28) |
159.9% | Details | |
| 2/7/2024 | Amgen | AMGN | Downgrade | Market Perform (Outperform) |
316.07 (381.27) |
20.63% | Details | |
| 10/11/2023 | Amgen | AMGN | Upgrade | Outperform (Market Perform) |
271.25 (381.27) |
40.56% | Details | |
| 9/12/2023 | Johnson & Johnson | JNJ | Maintain | Outperform (N/A) |
|
Details | ||
| 7/10/2023 | Bristol-Myers Squibb Co. | BMY | New Coverage | Market Perform (N/A) |
62.65 (63.76) |
1.77% | Details | |
| 3/17/2023 | Centessa Pharmaceuticals | CNTA | New Coverage | Outperform (N/A) |
4.00 (40.50) |
912.5% | Details | |
| 3/16/2023 | Halozyme Therapeutics | HALO | Downgrade | Market Perform (Outperform) |
40.05 (66.58) |
66.24% | Details | |
| 1/17/2023 | Vertex | VRTX | Upgrade | Outperform (Market Perform) |
300.94 (515.37) |
71.25% | Details | |
| 11/17/2022 | Theravance Biopharma | TBPH | Maintain | Outperform (N/A) |
|
Details | ||
| 11/2/2022 | Pfizer | PFE | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/11/2022 | Pfizer | PFE | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/20/2022 | Johnson & Johnson | JNJ | Maintain | Outperform (N/A) |
|
Details | ||
| 5/24/2022 | HilleVax, Inc. | HLVX | New Coverage | Outperform (N/A) |
9.50 (2.09) |
-78% | Details | |
| 5/23/2022 | Sanofi-Aventis | SNY | New Coverage | Market Perform (N/A) |
53.06 (42.68) |
-19.56% | Details | |
| 5/23/2022 | Johnson & Johnson | JNJ | New Coverage | Outperform (N/A) |
173.94 (154.14) |
-11.38% | Details | |
| 5/23/2022 | Roivant Sciences | ROIV | New Coverage | Outperform (N/A) |
3.65 (41.40) |
1034.25% | Details | |
| 5/23/2022 | Horizon Therapeutics | HZNP | New Coverage | Market Perform (N/A) |
89.34 (116.30) |
30.18% | Details | |
| 5/23/2022 | Vertex | VRTX | New Coverage | (N/A) |
255.45 (515.37) |
101.75% | Details | |
| 5/23/2022 | Theravance Biopharma | TBPH | New Coverage | Outperform (N/A) |
8.85 (17.02) |
92.32% | Details | |
| 5/23/2022 | Halozyme Therapeutics | HALO | New Coverage | Outperform (N/A) |
43.84 (107.61) |
145.46% | Details |
